- Home
- LXEH vs LSB Comparison
LXEH vs LSB Comparison
Compare LXEH & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- LSB
- Stock Information
- Founded
- LXEH 2001
- LSB 2002
- Country
- LXEH China
- LSB China
- Employees
- LXEH N/A
- LSB N/A
- Industry
- LXEH Other Consumer Services
- LSB
- Sector
- LXEH Real Estate
- LSB
- Exchange
- LXEH Nasdaq
- LSB NYSE
- Market Cap
- LXEH 25.1M
- LSB 22.3M
- IPO Year
- LXEH 2020
- LSB N/A
- Fundamental
- Price
- LXEH $1.40
- LSB $0.98
- Analyst Decision
- LXEH
- LSB
- Analyst Count
- LXEH 0
- LSB 0
- Target Price
- LXEH N/A
- LSB N/A
- AVG Volume (30 Days)
- LXEH 302.6K
- LSB 24.1K
- Earning Date
- LXEH 04-30-2025
- LSB 07-15-2025
- Dividend Yield
- LXEH N/A
- LSB N/A
- EPS Growth
- LXEH N/A
- LSB N/A
- EPS
- LXEH N/A
- LSB N/A
- Revenue
- LXEH $4,493,795.00
- LSB $79,415,311.00
- Revenue This Year
- LXEH N/A
- LSB $39.33
- Revenue Next Year
- LXEH N/A
- LSB $75.61
- P/E Ratio
- LXEH N/A
- LSB N/A
- Revenue Growth
- LXEH N/A
- LSB N/A
- 52 Week Low
- LXEH $1.20
- LSB $0.36
- 52 Week High
- LXEH $50.08
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- LXEH 34.46
- LSB 44.50
- Support Level
- LXEH $1.49
- LSB $0.93
- Resistance Level
- LXEH $1.85
- LSB $1.12
- Average True Range (ATR)
- LXEH 0.17
- LSB 0.07
- MACD
- LXEH 0.09
- LSB 0.02
- Stochastic Oscillator
- LXEH 25.13
- LSB 39.35
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.